More adults with moderate to severe atopic dermatitis receiving an investigational extended-release topical formulation vs. a vehicle treatment lowered their eczema severity by 50% in 4 weeks, according to interim phase 2 trial results.
The formulation, GX-03 (Turn Therapeutics), “provide[s] sustained localized exposure to polyhexanide at the skin surface,” according to the company press release.
In the ongoing randomized, double-blind, vehicle-controlled phase 2 trial, researchers are assessing adults with moderate to severe AD to determine the impact of GX-03 on eczema severity.
“The

Adults with MS had lower annualized relapse rates with diroximel fumarate vs. dimethyl fumarate treatment at 1 and 2 years, according to results published in Advances in Therapy.
“These findings may have a significant impact on everyday clinical practice,” Daniel S. Bandari, MD, MS, medical director and founder of the Multiple Sclerosis Center of California Clinic, Research Group and Infusion Center, told Healio. “While MS treatment aims to address individual patient needs due to the fact that MS is a very heterogeneous disease, efficacy remains a top priority.
“For those where fumarates are a

CHICAGO — A lifestyle program that includes low-glycemic index Mediterranean diet plus daily brisk walking and vitamin D supplementation can have significant impact on weight loss and metabolic syndrome among women with breast cancer.
Randomized phase 3 trial data, presented at ASCO Annual Meeting, showed that a high-intensity lifestyle intervention significantly improved body weight, BMI, HDL cholesterol and metabolic syndrome compared with standard advice on Mediterranean diet and physical activity while keeping serum vitamin D at sufficient levels.
“We saw a huge difference,” Livia S.

Evidence suggests inflammatory bowel disease is equally prevalent in transgender and cisgender populations. However, it remains unclear whether gender-affirming care and the higher rates of trauma experienced by many transgender patients affect disease course.
As political pressure threatens access to gender-affirming hormone therapy (GAHT), patients with IBD who are transgender are increasingly caught in an uncertain care landscape. Major knowledge gaps remain around how hormone therapy may affect Crohn’s disease and ulcerative colitis, as well as the psychosocial challenges of being